Table 3.

Summary of adverse events reported by at least 5% of the participants after any treatment, n = 48

Adverse event	PBO(n = 48)n (%)	LEM2.5(n = 32)n (%)	LEM5(n = 32)n (%)	LEM10(n = 32)n (%)	ZOP(n = 48)n (%)
Somnolence	3 (6.3)	3 (9.4)	3 (9.4)	10 (31.3)	8 (16.7)
Headache	8 (16.7)	4 (12.5)	3 (9.4)	2 (6.3)	1 (2.1)
Dizziness	1 (2.1)	2 (6.3)	0 (0.0)	0	3 (6.3)
Dysgeusia	1 (2.1)	0 (0.0)	0 (0.0)	0	7 (14.6)
Dry mouth	1 (2.1)	3 (9.4)	1 (3.1)	3 (9.4)	2 (4.2)
Nausea	0	0	0	2 (6.3)	0
Fatigue	1 (2.1)	0	2 (6.3)	2 (6.3)	0
Influenza	0	2 (6.3)	1 (3.1)	2 (6.3)	0
Back pain	1 (2.1)	0	0	2 (6.3)	0

PBO, placebo; LEM2.5, lemborexant 2.5 mg; LEM5, lemborexant 5 mg; LEM10, lemborexant 10 mg; ZOP, zopiclone 7.5 mg.